Blood cancers, Cell type, High grade lymphoma, Lymphoma, Non-Hodgkin lymphoma (NHL)
Results
Phase 1/2
This trial looked at 2 drugs called romidepsin and carfilzomib for people with T cell lymphoma.
It was for people with peripheral T cell lymphoma that had come back (relapsed) or treatment had stopped working (refractory).
The trial was open for people to join between 2015 and 2019. The team reported the results in 2022.
Recruitment start: 31 July 2015
Recruitment end: 14 October 2019
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Graham Collins
Blood Cancer UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University of Birmingham
Last reviewed: 4 December 2024
CRUK internal database number: 11008
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
